Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 210Recurrence 26Neoplasms, Plasma Cell 15Neoplasms 13Immunoglobulin Light-chain Amyloidosis 13Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Smoldering Multiple Myeloma 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Hematologic Neoplasms 4Plasmacytoma 3Paraproteinemias 3Myelodysplastic Syndromes 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Amyloidosis 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Plasmablastic Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Disease 2Corneal Diseases 2Blood Protein Disorders 2

Interventions

Dexamethasone 8Lenalidomide 4dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3auricularum 3Calcium Dobesilate 3Bortezomib 3pomalidomide 2ixazomib 2filanesib 2Steroids 2Radiotherapy 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1milatuzumab 1cc-486 1carfilzomib 1Thalidomide 1Specimen Handling 1Sodium Selenite 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Plasmacytoma × daratumumab × Clear all
NCT01946477 2026-05-22

POM MM 014

Celgene

Phase 2 Completed
186 enrolled 17 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Completed
498 enrolled 15 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT04065308 2019-08-22

Dara_DCEP

Seoul National University Hospital

Phase 2 Unknown
33 enrolled
Plasma cell

Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡